Multiple disguises for the same party: The concepts of morphogenesis and phenotypic variations in Cryptococcus neoformans

Frontiers in Microbiology

Volumn 2, Issue SEP, 2011, Pages

  Zaragoza, Oscar ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antigenic variations; Capsule enlargement; Cryptococcus neoformans; Giant cells; Micro cells; Morphogenesis

Indexed keywords

FILOBASIDIELLA NEOFORMANS; FUNGI;

EID: 84858067921     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2011.00181     Document Type: Article

References (102)

1. Aksenov, S. I., Babyeva, I. P., and Gol-ubev, V. I. (1973). On the mechanism of adaptation of microorganisms to conditions of extreme low humidity. Life Sci. Space Res. 11, 55-61.
2. Anna, E. J. (1979). Rapid in vitro capsule production by crypto-cocci. Am. J. Med. Technol. 45, 585-588.
3. Bose, I., Reese, A. J., Ory, J. J., Janbon, G., and Doering, T.L. (2003). Ayeast under cover: the capsule of Cryptococcus neoformans. Eukaryot. Cell 2, 655-663.
4. Casadevall, A., Deshaw, M., Fan, M., Dromer, F., Kozel, T. R., and Pirofski, L. A. (1994). Molecular andidiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxyloman-nan. Infect. Immun. 62, 3864-3872.
5. Casadevall, A., Mukherjee, J., Devi, S. J., Schneerson, R., Robbins, J. B., and Scharff, M. D. (1992). Antibodies elicited by a Cryptococcus neoformans-tetanus tox-oid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 165, 1086-1093.
6. Casadevall, A., and Perfect, J. R. (1998). Cryptococcus neoformans. Washington, DC: ASM Press. Chang, Y. C., and Kwon-Chung, K. J. (1994). Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol. Cell. Biol. 14, 4912-4919.
7. Chang, Y. C., and Kwon-Chung, K. J. (1998). Isolation of the third capsule-associated gene, CAP60, required for virulence in Cryptococcus neoformans. Infect. Immun. 66, 2230-2236.
8. Chang, Y C, and Kwon-Chung, K. J. (1999). Isolation, characterization, and localization of a capsule-associated gene, CAP 10, of Cryptococcus neoformans. J. Bacteriol. 181, 5636-5643.
9. Chang, Y C, Wickes, B. L., and Kwon-Chung, K. J. (1995). Further analysis of the CAP59 locus of Cryptococcus neoformans: structure defined by forced expression and description of a new ribosomal protein-encoding gene. Gene 167, 179-183.
10. Charlier, C., Chretien, F., Baudrimont, M., Mordelet, E., Lortholary, O., and Dromer, E (2005). Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am. J. Pathol. 166,421-432.
11. Cherniak, R., Jones, R. G., and Reiss, E. (1988a). Structure determination of Cryptococcus neoformans serotype A-variant glucuronoxylomannan by 13C-n.m.r. spectroscopy. Carbohydr. Res. 172,113-138.
12. Cherniak, R., Jones, R. G., and Slodki, M. E. (1988b). Type-specific polysaccharides of Cryptococcus neoformans. n.m.r.-spectral study of a glucuronomannan chemically derived from a Tremella mesen-terica exopolysaccharide. Carbohydr. Res. 182, 227-239.
13. Cherniak, R., Morris, L. C., Belay, T., Spitzer, E. D., and Casadevall, A. (1995). Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent crypto-coccal meningitis. Infect. Immun. 63, 1899-1905.
14. Cherniak, R., Reiss, E., Slodki, M. E., Plattner, R. D., and Blumer, S. O. (1980). Structure and antigenic activity of the capsular polysac-charide of Cryptococcus neoformans serotype A. Mol. Immunol. 17, 1025-1032.
15. Cherniak, R., Reiss, E., and Turner, S. (1982). A galactoxylomannan antigen of Cryptococcus neoformans serotype A. Carbohydr. Res. 103, 239-250.
16. Cherniak, R., and Sundstrom, J. B.(1994). Polysaccharide anti gens of the capsule of Cryptococ cus neoformans. Infect. Immun. 62, 1507-1512.
17. Cherniak, R., Valafar, H., Morris, L. C., and Valafar, F. (1998). Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network. Clin. Diagn. Lab. Immunol. 5,146-159.
18. Chrisman, C. J., Albuquerque, P., Guimaraes, A. J., Nieves, E., and Casadevall, A. (2011). Phos-pholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages. PLoS Pathog. 7, e1002047. doi: 10.1371/journal.ppat.1002047
19. Cleare, W., and Casadevall, A. (1998). The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays. Clin. Diagn. Lab. Immunol. 5, 125-129.
20. Cordero, R. J., Frases, S., Guimaraes, A. J., Rivera, J., and Casadevall, A. (2011). Evidence for branching in cryptococcal capsular polysaccha-rides and consequences on its biological activity. Mol. Microbiol. 79, 1101-1117.
21. Cruickshank, J. G., Cavill, R., and Jelbert, M. (1973). Cryptococcus neoformans of unusual morphology. Appl. Microbiol. 25, 309-312.
22. De Jesus, M. D., Nicola, A. M., Chow, S. K., Lee, I. R., Nong, S., Specht, C. A., Levitz, S. M., and Casadevall, A. (2010). Glucuronoxylomannan, galactoxylomannan, and manno-protein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans. Virulence 1, 500-508.
23. Diamond, R. D., and Bennett, J. E. (1973). Growth of Cryptococcus neoformans within human macrophages in vitro. Infect. Immun. 7,231-236.
24. Doering, T.L. (2000). How does Cryptococcus get its coat? Trends Microbiol. 8, 547-553.
25. Dromer, F., Casadevall, A., Perfect, J. R., and Sorrell, T. C. (2011). "Cryptococcus neoformans: latency and disease," in Cryptococcus. From Human Pathogen to Model Yeast, eds J. Heit-man, T. R. Kozel, K. J. Kwon-Chung, J. R. Perfect, and A. Casadevall (Washington, DC: ASM Press), 431-439.
26. Dromer, F., Charreire, J., Contrepois, A., Carbon, C., and Yeni, P. (1987). Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55, 749-752.
27. Dromer, F., Mathoulin-Pelissier, S., Lau-nay, O., and Lortholary, O. (2007). Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoSMed. 4,e21. doi: 10.1371/jour-nal.pmed.0040021
28. Eckert, T. F., and Kozel, T. R. (1987). Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55, 1895-1899.
29. Ellerbroek, P. M., Hoepelman, A. I., Wolbers, F., Zwaginga, J. J., and Coenjaerts, F. E. (2002). Cryptococcal glucuronoxylomannan inhibits adhesion of neutrophils to stimulated endothelium in vitro by affecting both neutrophils and endothelial cells. Infect. Immun. 70, 4762-4771.
30. Feldmesser, M., Kress, Y., and Casadevall, A. (2001). Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology 147, 2355-2365.
31. Frases, S., Nimrichter, L., Viana, N. B., Nakouzi, A., and Casadevall, A. (2008). Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot. Cell 7,319-327.
32. Frases, S., Pontes, B., Nimrichter, L., Viana, N. B., Rodrigues, M. L., and Casadevall, A. (2009). Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules. Proc. Natl. Acad. Sci. U.S.A. 106, 1228-1233.
33. French, M. A. (2009). HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin. Infect. Dis. 48, 101-107.
34. Gahrs, W., Tigyi, Z., Emody, L., and Makovitzky, J. (2009). Polarization optical analysis of the surface structures of various fungi. Acta His-tochem. 111,308-315.
35. Garcia-Hermoso, D., Dromer, F., and Janbon, G. (2004). Cryptococcus neoformans capsule structure evolution in vitro and during murine infection. Infect. Immun. 72, 3359-3365.
36. Garcia-Rodas, R., Casadevall, A., Rodriguez-Tudela, J. L., Cuenca-Estrella, M., and Zaragoza, O. (2011). Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS ONE (in press).
37. Gates, M. A., and Kozel, T. R. (2006). Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans. Infect. Immun. 74, 3096-3106.
38. Gates, M. A., Thorkildson, P., and Kozel, T. R. (2004). Molecular architecture of the Cryptococcus neoformans capsule. Mol. Microbiol. 52,13-24.
39. Gates-Hollingsworth, M. A., and Kozel, T. R. (2009). Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule. Mol. Microbiol. 74, 126-138.
40. Gazzoni, A. F., Oliveira Fde, M., Salles, E. F., Mayayo, E., Guarro, J., Capilla, J., and Severo, L. C. (2010). Unusual morphologies of Cryptococcus spp. in tissue specimens: report of 10 cases. Rev. Inst. Med. Trop. Sao Paulo 52, 145-149.
41. Goldman, D. L., Fries, B. C., Fran-zot, S. P., Montella, L., and Casadevall, A. (1998). Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc. Natl. Acad. Sci. U.S.A. 95, 14967-14972.
42. Granger, D. L., Perfect, J. R., and Durack, D. T. (1985). Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J. Clin. Invest. 76, 508-516.
43. Guerrero, A., Jain, N., Wang, X., and Fries, B. C. (2010). Cryptococcus neoformans variants generated by phenotypic switching differ in virulence through effects on macrophage activation. Infect. Immun. 78,1049-1057.
44. Guimaraes, A. J., Frases, S., Cordero, R. J., Nimrichter, L., Casadevall, A., and Nosanchuk, J. D. (2010). Cryptococcus neoformans responds to manni-tol by increasing capsule size in vitro and in vivo. Cell. Microbiol. 12, 740-753.
45. Heiss, C., Klutts, J. S., Wang, Z., Doering, T.L., and Azadi, P. (2009). The structure of Cryptococcus neoformans galactoxylomannan contains beta-D-glucuronic acid. Carbohydr. Res. 344,915-920.
46. Heitman, J., Kozel, T. R., Kwon-Chung, K. J., Perfect, J. R., and Casadevall, A. (2011). Cryptococcus. From Human Pathogen to Model Yeast. Washington, DC: ASM Press.
47. Hosseini-Moghaddam, S. M., and Husain, S. (2010). Fungi and molds following lung transplantation. Semin. Respir. Crit. Care Med. 31,222-233.
48. Janbon, G. (2004). Cryptococcus neoformans capsule biosynthesis and regulation. FEMS Yeast Res. 4, 765-771.
49. Janbon, G., and Doering, T. L. (2011). "Biosynthesis and genetics of the Cryptococcus capsule," in Cryptococcus. From human Pathogen to Model Yeast, eds J. Heitman, T. R. Kozel, K. J. Kwon-Chung, J. R. Perfect, and A. Casadevall (Washington, DC: ASM Press), 27-41.
50. Janbon, G., Himmelreich, U., Moyrand, E, Improvisi, L., and Dromer, E (2001). Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharide. Mol. Microbiol. 42,453-467.
51. Kane, J. (1984). Conversion of Blasto-myces dermatitidis to the yeast form at 37 degrees C and 26 degrees C. J. Clin. Microbiol. 20, 594-596.
52. Kozel, T. R., Gulley, W E, and Cazin, J. Jr. (1977). Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect. Immun. 18, 701-707.
53. Kozel, T. R., Levitz, S. M., Dromer, F., Gates, M. A., Thorkildson, P., and Janbon, G. (2003). Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains. Infect. Immun. 71,2868-2875.
54. Kozubowski, L., and Heitman, J. (2011). Profiling a killer, the development of Cryptococcus neoformans. FEMS Microbiol. Rev. doi: 10.1111/j.1574-6976.2011.00286.x. [Epub ahead of print].
55. Kurtzman, C. P., and Fell, J. W (1997). The Yeasts: A Taxonomical Study. Amsterdam: Elsevier.
56. Levitz, S. M., Nong, S. H., Seetoo, K. R, Harrison, T. S., Speizer, R. A., and Simons, E. R. (1999). Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect. Immun. 67, 885-890.
57. Levitz, S. M., and Specht, C. A. (2006). The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast Res. 6, 513-524.
58. Lipovsky M. M., Tsenova, L., Coen-jaerts, F. E., Kaplan, G., Cher-niak, R., and Hoepelman, A. I. (2000). Cryptococcal glucuronoxy-lomannan delays translocation of leukocytes across the blood-brain barrier in an animal model of acute bacterial meningitis. J. Neuroim-munol. 111, 10-14.
59. Littman, M. (1958). Capsule synthesis by Cryptococcus neoformans. Trans. N. Y.Acad. Sci. 20, 623-648.
60. Liu, O. W., Chun, C. D., Chow, E. D., Chen, C., Madhani, H. D., and Noble, S. M. (2008). Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans. Cell 135, 174-188.
61. Ma, H., Croudace, J. E., Lammas, D. A., and May, R. C. (2006). Expulsion of live pathogenic yeast by macrophages. Curr. Biol. 16, 2156-2160.
62. Macher, A. M., Bennett, J. E., Gadek, J. E., and Frank, M. M. (1978). Complement depletion in cryptococcal sepsis.J. Immunol. 120,1686-1690.
63. Maresca, B., and Kobayashi, G. S. (1989). Dimorphism in Histoplasma capsulatum: a model for the study of cell differentiation in pathogenic fungi. Microbiol Rev. 53, 186-209.
64. Maxson, M. E., Cook, E., Casadevall, A., and Zaragoza, O. (2007a). The volume and hydration of the Cryp tococ-cus neoformans polysaccharide capsule. Fungal Genet. Biol. 44,180-186.
65. Maxson, M. E., Dadachova, E., Casadevall, A., and Zaragoza, O. (2007b). Radial mass density, charge, and epi-tope distribution in the Cryptococcus neoformans capsule. Eukaryot. Cell 6, 95-109.
66. McFadden, D., Zaragoza, O., and Casadevall, A. (2006a). The capsular dynamics of Cryptococcus neoformans. Trends Microbiol. 14, 497-505.
67. McFadden, D. C., De Jesus, M., and Casadevall, A. (2006b). The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction.J. Biol. Chem. 281, 1868-1875.
68. McFadden, D. C., Fries, B. C., Wang, E, and Casadevall, A. (2007). Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans. Eukaryot. Cell 6, 1464-1473.
69. McFadden, D. C., Zaragoza, O., and Casadevall, A. (2004). Immunoreac-tivity of cryptococcal antigen is not stable under prolonged incubations in human serum. J. Clin. Microbiol. 42,2786-2788.
70. Monari, C., Bistoni, F., and Vec-chiarelli, A. (2006). Glucuronoxylo-mannan exhibits potent immuno-suppressive properties. FEMS Yeast Res. 6, 537-542.
71. Mukherjee, J., Kozel, T. R., and Casadevall, A. (1998). Monoclonal antibodies reveal additional epi-topes of serotype D Cryptococcus neoformans capsular glucuronoxylo-mannan that elicit protective antibodies. J. Immunol. 161, 3557-3568.
72. Murphy, J. W., and Cozad, G. C. (1972). Immunological unrespon-siveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect. Immun. 5, 896-901.
73. Neilson, J. B., Ivey, M. H., and Bulmer, G. S. (1978). Cryptococcus neoformans: pseudohyphal forms surviving culture with Acanthamoeba polyphaga. Infect. Immun. 20, 262-266.
74. Netski, D., and Kozel, T. R. (2002). Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity. Infect. Immun. 70,2812-2819.
75. Nimrichter, L., Frases, S., Cinelli, L. P., Viana, N. B., Nakouzi, A., Travassos, L. R., Casadevall, A., and Rodrigues, M. L. (2007). Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot. Cell 6, 1400-1410.
76. Nosanchuk, J. D., and Casadevall, A. (2003). The contribution of melanin to microbial pathogenesis. Cell. Microbiol. 5, 203-223.
77. Okagaki, L. H., Strain, A. K., Nielsen, J. N., Charlier, C., Baltes, N. J., Chretien, F., Heitman, J., Dromer, E, and Nielsen, K. (2010). Cryptococcal cell morphology affects host cell interactions and pathogenic-ity. PLoS Pathog. 6, e1000953. doi: 10.1371/journal.ppat.1000953
78. Okagaki, L. H., Wang, Y., Ballou, E. R., O'meara, T. R., Bahn, Y. S., Alspaugh, J. A., Xue, C., and Nielsen, K. (2011). Cryptococcal titan cell formation is regulated by G-protein signaling in response to multiple stimuli. Eukaryot. Cell. doi: 10.1128/EC.05179-11. [Epub ahead of print].
79. Park, B. I., Wannemuehler, K. A., Marston, B. J., Govender, N., Pappas, P. G., and Chiller, T. M. (2009). Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23,525-530.
80. Pierini, L. M., and Doering, T. L. (2001). Spatial and temporal sequence of capsule construction in Cryptococcus neoformans. Mol. Microbiol. 41, 105-115.
81. Pirofski, L., Lui, R., Deshaw, M., Kres-sel, A. B., and Zhong, Z. (1995). Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect. Immun. 63,3005-3014.
82. Rodrigues, M. L., Alvarez, M., Fon-seca, F. L., and Casadevall, A. (2008). Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan. Eukaryot. Cell 7, 602-609.
83. Rodrigues, M. L., Casadevall, A., and Zaragoza, O. (2011). "The architecture and antigenic composition of the polysaccharide capsule," in Cryptococcus. From Human Pathogen to Model Yeast, eds J. Heitman, T. R. Kozel, K. J. Kwon-Chung, J. R. Perfect, and A. Casadevall (Washington, DC: ASM Press), 43-54.
84. Rodrigues, M. L., Nimrichter, L., Oliveira, D. L., Frases, S., Miranda, K., Zaragoza, O., Alvarez, M., Nakouzi, A., Feldmesser, M., and Casadevall, A. (2007). Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot. Cell 6, 48-59.
85. Singh, N., and Forrest, G. (2009). Cryp-tococcosis in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S192-S198.
86. Taborda, C. P., and Casadevall, A. (2002). CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity 16,791-802.
87. Todaro-Luck, F., Reiss, E., Cherniak, R., and Kaufman, L. (1989). Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies. Infect. Immun. 57, 3882-3887.
88. Tucker, S. C., and Casadevall, A. (2002). Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal per-meabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc. Natl. Acad. Sci. U.S.A. 99, 3165-3170.
89. van de Moer, A., Salhi, S. L., Cherniak, R., Pau, B., Garrigues, M. L., and Bastide, J. M. (1990). An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan. Res. Immunol. 141, 33-42.
90. Vartivarian, S. E., Anaissie, E. J., Cow-art, R. E., Sprigg, H. A., Tingler, M. J., and Jacobson, E. S. (1993). Regulation of cryptococcal capsular polysaccharide by iron. J. Infect. Dis. 167, 186-190.
91. Vecchiarelli, A. (2000). Immunoreg-ulation by capsular components of Cryptococcus neoformans. Med. Mycol. 38,407-417.
92. Whiteway, M., and Bachewich, C. (2007). Morphogenesis in Candida albicans. Annu. Rev. Microbiol. 61, 529-553.
93. Williamson, J. D., Silverman, J. F., Mal-lak, C. T., and Christie, J. D. (1996). Atypical cytomorphologic appearance of Cryptococcus neoformans: a report of five cases. Acta Cytol. 40, 363-370.
94. Young, B. J., and Kozel, T. R. (1993). Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect. Immun. 61,2966-2972.
95. Zaragoza, O., and Casadevall, A. (2004). Experimental modulation of capsule size in Cryptococcus neoformans. Biol. Proced. Online 6, 10-15.
96. Zaragoza, O., and Casadevall, A. (2006). Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance. Cell. Microbiol. 8, 1862-1876.
97. Zaragoza, O., Chrisman, C. J., Castelli, M. V., Frases, S., Cuenca-Estrella, M., Rodriguez-Tudela, J. L., and Casadevall, A. (2008). Capsule enlargement in Cryptococcus neoformans confers resistance to oxi dative stress suggesting a mechanism for intracel-lular survival. Cell. Microbiol. 10, 2043-2057.
98. Zaragoza, O., Fries, B. C., and Casadevall, A. (2003a). Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect. Immun. 71, 6155-6164.
99. Zaragoza, O., Taborda, C. P., and Casadevall, A. (2003b). The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur. J. Immnunol. 33, 1957-1967.
100. Zaragoza, O., Garcia-Rodas, R., Nosanchuk, J. D., Cuenca-Estrella, M., Rodriguez-Tudela, J. L., and Casadevall, A. (2010). Fungal cell gigantism during mammalian infection. PLoS Pathog. 6, e1000945. doi: 10.1371/journal. ppat. 1000945
101. Zaragoza, O., Rodrigues, M. L., De Jesus, M., Frases, S., Dadachova, E., and Casadevall, A. (2009). The capsule of the fungal pathogen Cryptococcus neoformans. Adv. Appl. Microbiol. 68, 133-216.
102. Zaragoza, O., Telzak, A., Bryan, R. A., Dadachova, E., and Casadevall, A. (2006). The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol. 59, 67-83.